FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Metastatic Castration-resistant Prostate Cancer	Active, not recruiting	Phase 2	2026-04-08		NCT06402331

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Fusion Pharmaceuticals Inc.	3

18 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
BAMF Health	Grand Rapids	United States	15
Biogenix Molecular, LLC	Miami	United States	7
City of Hope Comprehensive Cancer Center	Duarte	United States	263
Hoag Health Center Irvine	Irvine	United States	6
Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York	United States	188
Memorial Sloan Kettering Cancer Center - NYC	New York	United States	2
New Mexico Oncology Hematology Consultants Ltd.	Albuquerque	United States	2
Oregon Health and Science University (OHSU, Knight Cancer Center)	Portland	United States	1
SSM Health Saint Louis University Hospital	St Louis	United States	18
The University of Texas Southwestern Medical Center	Dallas	United States	37
U.T. MD Anderson Cancer Center	Houston	United States	7
UCSF School of Medicine	San Francisco	United States	2
United Theranostics	Glen Burnie	United States	9
University of California Los Angeles	Los Angeles	United States	87
University of Iowa Hospitals and Clinics	Iowa City	United States	99
VA Greater Los Angeles Healthcare System	Los Angeles	United States	15
VA North Texas Health Care System, Nuclear Medicine Service	Dallas	United States	1
XCancer	Omaha	United States	7